title: Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial.
abstract: beta-Blockers and endoscopic variceal ligation (EVL) have proven to be valuable methods in the prevention of variceal rebleeding. The aim of this study was to compare the efficacy of EVL combined with nadolol versus EVL alone as secondary prophylaxis for variceal bleeding. Patients admitted for acute variceal bleeding were treated during emergency endoscopy with EVL or sclerotherapy and received somatostatin for 5 days. At that point, patients were randomized to receive EVL plus nadolol or EVL alone. EVL sessions were repeated every 10 to 12 days until the varices were eradicated. Eighty patients with cirrhosis (alcoholic origin in 66%) were included (Child-Turcotte-Pugh A, 15%; B, 56%; C, 29%). The median follow-up period was 16 months (range, 1-24 months). The variceal bleeding recurrence rate was 14% in the EVL plus nadolol group and 38% in the EVL group (P = .006). Mortality was similar in both groups: five patients (11.6%) died in the combined therapy group and four patients (10.8%) died in the EVL group. There were no significant differences in the number of EVL sessions to eradicate varices: 3.2 +/- 1.3 in the combined therapy group versus 3.5 +/- 1.3 in the EVL alone group. The actuarial probability of variceal recurrence at 1 year was lower in the EVL plus nadolol group (54%) than in the EVL group (77%; P = .06). Adverse effects resulting from nadolol were observed in 11% of the patients. In conclusion, nadolol plus EVL reduces the incidence of variceal rebleeding compared with EVL alone. A combined treatment could lower the probability of variceal recurrence after eradication.
authors.affiliation: Hospital Universitario Marques de Valdecilla, Santander, Spain. jpena@humv.es
authors.forename: Joaquin
authors.initials: J
authors.lastname: de la Peña
authors.forename: Enric
authors.initials: E
authors.lastname: Brullet
authors.forename: Eloy
authors.initials: E
authors.lastname: Sanchez-Hernández
authors.forename: Monserrat
authors.initials: M
authors.lastname: Rivero
authors.forename: Mercedes
authors.initials: M
authors.lastname: Vergara
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Martin-Lorente
authors.forename: Covadonga
authors.initials: C
authors.lastname: Garcia Suárez
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004932:Esophageal and Gastric Varices / Q000150:complications*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008026:Ligation; D008297:Male; D008875:Middle Aged; D009248:Nadolol / Q000627:therapeutic use*; D011446:Prospective Studies; D012008:Recurrence
chemical_list: D000319:Adrenergic beta-Antagonists; D009248:Nadolol